BioSpace News Archive

The latest market analysis report published by Reports and Data, titled ‘Global Postsurgical Pain Market – Forecast to 2030,’ thoroughly examines the Postsurgical Pain industry to provide essential data & information for the targeted readers.

The latest market analysis report published by Reports and Data, titled ‘Global Thrombocytopenia Market – Forecast to 2030,’ thoroughly examines the Thrombocytopenia industry to provide essential data & information for the targeted readers.

According to Nova one advisor, the global Overactive Bladder Treatment (OAB) market size is expected to hit around USD 8.2 billion by 2030 from valued at USD 3.9 billion in 2022 and growing at a CAGR of 4.6% from 2022 to 2030.

CSL Seqirus announced that the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, selected CSL Seqirus to deliver an H5N8 A/Astrakhan virus vaccine candidate for assessment in a Phase 2 clinical study that is anticipated to begin in Q2 2023.

Hugel America, Inc. (Hugel Aesthetics) announced today that it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for letibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines.

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its third quarter 2022 financial results on Wednesday, November 2, 2022.

Rhythm Pharmaceuticals, Inc. announced that on October 3, 2022, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 138,495 shares of its common stock to 10 new employees, consisting of inducement stock options to purchase an aggregate of 92,525 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 45,970 shares of its common stock.

Rhythm Pharmaceuticals, Inc. announced the appointment of Dana Washburn, M.D., as Senior Vice President of Clinical Development and as a member of the Company’s Executive Leadership Team, effective September 26, 2022.

Haemonetics Corporation announced that the Company intends to publish second quarter fiscal year 2023 financial results at 6:00 am ET on Monday, November 7, 2022.

Accuray Incorporated announced that the company will host a key opinion leader discussion with analysts and investors on Monday, October 24, 2022, in conjunction with the American Society of Radiation Oncology Annual Meeting.